New cardiac test launch puts IDEXX Laboratories stock in focus

IDEXX Laboratories (IDXX) has drawn fresh investor attention after announcing the Catalyst proBNP Test, a dual species in-clinic NT proBNP assay that extends its cardiac diagnostics offering for companion animals.

The cardiac test launch arrives during a weaker patch for IDEXX Laboratories’ share price, with the stock down 17.41% year to date on a share price basis and total shareholder return also mixed over longer periods.

If this kind of healthcare innovation has your attention, it could be a good time to widen your radar and review our screener of 42 healthcare AI stocks

For IDEXX Laboratories, a 17.41% share price decline this year sits against growing cardiac offerings like Catalyst proBNP. Is the stock now mainly reflecting sentiment swings or the fundamentals you are actually paying for?

Most Popular Narrative: 22% Undervalued

The most followed narrative on IDEXX Laboratories compares a fair value of $709.14 with the recent $553.32 close, suggesting the current price is below that fair value estimate while still reflecting meaningful expectations about growth and profitability.

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

Want to see what sits behind that fair value for IDEXX Laboratories? The narrative leans heavily on recurring diagnostics revenue, higher margins, and a rich future earnings multiple.

Result: Fair Value of $709.14 (UNDERVALUED)

However, IDEXX Laboratories still faces real pressure if veterinary visit growth remains soft or if international clinics adopt diagnostics more slowly than analysts currently assume.

Another View on IDEXX Laboratories Valuation

The narrative fair value suggests IDEXX Laboratories is 7.5% below an estimated $598.16 future cash flow value. Yet the current P/E of 38.2x is well above the Medical Equipment industry at 26x, a peer average of 34.5x, and a fair ratio of 29.1x. Consider whether that premium aligns with your risk tolerance and investment approach.

Next Steps

If the mixed tone of IDEXX Laboratories in this article has you weighing both upside and risk, it makes sense to move quickly and test the numbers yourself. To see both sides of the story in one place, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond IDEXX Laboratories?

If IDEXX Laboratories has sharpened your focus, do not stop here. Use fresh ideas to pressure test your portfolio and avoid missing opportunities others overlook.

• Spot potential bargains early by scanning the 50 high quality undervalued stocks that combine quality fundamentals with prices that may be lagging business performance.
• Strengthen your income stream by reviewing the 11 dividend fortresses that could support more consistent cash returns.
• Reduce portfolio stress by concentrating on the 79 resilient stocks with low risk scores that score well on financial resilience and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.